Transmission genetics of drug-resistant hepatitis C virus

  1. Nicholas van Buuren
  2. Timothy L Tellinghuisen
  3. Christopher C Richardson
  4. Karla Kirkegaard  Is a corresponding author
  1. Stanford University School of Medicine, United States
  2. The Scripps Research Institute, United States
  3. Dalhousie University, Canada

Abstract

Antiviral development is plagued by drug resistance and genetic barriers to resistance are needed. For HIV and hepatitis C virus (HCV), combination therapy has proved life-saving. The targets of direct-acting antivirals for HCV infection are NS3/4A protease, NS5A phosphoprotein and NS5B polymerase. Differential visualization of drug-resistant and -susceptible RNA genomes within cells revealed that resistant variants of NS3/4A protease and NS5A phosphoprotein are cis-dominant, ensuring their direct selection from complex environments. Confocal microscopy revealed that RNA replication complexes are genome-specific, rationalizing the non-interaction of wild-type and variant products. No HCV antivirals yet display the dominance of drug susceptibility shown for capsid proteins of other viruses. However, effective inhibitors of HCV polymerase exact such high fitness costs for drug resistance that stable genome selection is not observed. Barriers to drug resistance vary with target biochemistry and detailed analysis of these barriers should lead to the use of fewer drugs.

Article and author information

Author details

  1. Nicholas van Buuren

    Department of Genetics, Stanford University School of Medicine, Stanford, United States
    Competing interests
    No competing interests declared.
  2. Timothy L Tellinghuisen

    Department of Infectious Diseases, The Scripps Research Institute, Jupiter, United States
    Competing interests
    No competing interests declared.
  3. Christopher C Richardson

    Department of Microbiology and Immunology, Dalhousie University, Halifax, Canada
    Competing interests
    No competing interests declared.
  4. Karla Kirkegaard

    Department of Genetics, Stanford University School of Medicine, Stanford, United States
    For correspondence
    karlak@stanford.edu
    Competing interests
    Karla Kirkegaard, Reviewing editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7628-3770

Funding

National Institutes of Health (U19-AI09662)

  • Karla Kirkegaard

Canadian Institutes of Health Research (NCRTP-HepC Postdoctoral Fellowship)

  • Nicholas van Buuren

American Liver Foundation (Postdoctoral Fellowship)

  • Nicholas van Buuren

National Institutes of Health (NIH Director's Pioneer Award)

  • Karla Kirkegaard

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. David M Knipe, Harvard Medical School, United States

Publication history

  1. Received: October 6, 2017
  2. Accepted: March 22, 2018
  3. Accepted Manuscript published: March 28, 2018 (version 1)
  4. Version of Record published: April 25, 2018 (version 2)
  5. Version of Record updated: November 29, 2018 (version 3)

Copyright

© 2018, van Buuren et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,895
    Page views
  • 286
    Downloads
  • 4
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Nicholas van Buuren
  2. Timothy L Tellinghuisen
  3. Christopher C Richardson
  4. Karla Kirkegaard
(2018)
Transmission genetics of drug-resistant hepatitis C virus
eLife 7:e32579.
https://doi.org/10.7554/eLife.32579

Further reading

    1. Computational and Systems Biology
    2. Genetics and Genomics
    Aaron W Jurrjens, Marcus M Seldin ... Anna C Calkin
    Review Article

    Cardiometabolic diseases encompass a range of interrelated conditions that arise from underlying metabolic perturbations precipitated by genetic, environmental, and lifestyle factors. While obesity, dyslipidaemia, smoking, and insulin resistance are major risk factors for cardiometabolic diseases, individuals still present in the absence of such traditional risk factors, making it difficult to determine those at greatest risk of disease. Thus, it is crucial to elucidate the genetic, environmental, and molecular underpinnings to better understand, diagnose, and treat cardiometabolic diseases. Much of this information can be garnered using systems genetics, which takes population-based approaches to investigate how genetic variance contributes to complex traits. Despite the important advances made by human genome-wide association studies (GWAS) in this space, corroboration of these findings has been hampered by limitations including the inability to control environmental influence, limited access to pertinent metabolic tissues, and often, poor classification of diseases or phenotypes. A complementary approach to human GWAS is the utilisation of model systems such as genetically diverse mouse panels to study natural genetic and phenotypic variation in a controlled environment. Here, we review mouse genetic reference panels and the opportunities they provide for the study of cardiometabolic diseases and related traits. We discuss how the post-GWAS era has prompted a shift in focus from discovery of novel genetic variants to understanding gene function. Finally, we highlight key advantages and challenges of integrating complementary genetic and multi-omics data from human and mouse populations to advance biological discovery.

    1. Genetics and Genomics
    2. Medicine
    Joshua K Park, Shantanu Bafna ... Ron Do
    Research Article

    Background: Causality between plasma triglyceride (TG) levels and atherosclerotic cardiovascular disease (ASCVD) risk remains controversial despite more than four decades of study and two recent landmark trials, STRENGTH and REDUCE-IT. Further unclear is the association between TG levels and non-atherosclerotic diseases across organ systems.

    Methods: Here, we conducted a phenome-wide, two-sample Mendelian randomization (MR) analysis using inverse-variance weighted (IVW) regression to systematically infer the causal effects of plasma TG levels on 2,600 disease traits in the European ancestry population of UK Biobank. For replication, we externally tested 221 nominally significant associations (p < 0.05) in an independent cohort from FinnGen. To account for potential horizontal pleiotropy and the influence of invalid instrumental variables, we performed sensitivity analyses using MR-Egger regression, weighted median estimator, and MR-PRESSO. Finally, we used multivariable MR controlling for correlated lipid fractions to distinguish the independent effect of plasma TG levels.

    Results: Our results identified 7 disease traits reaching Bonferroni-corrected significance in both the discovery (p < 1.92 × 10-5) and replication analyses (p < 2.26 × 10-4), suggesting a causal relationship between plasma TG levels and ASCVDs, including coronary artery disease (OR 1.33, 95% CI 1.24-1.43, p = 2.47 × 10-13). We also identified 12 disease traits that were Bonferroni-significant in the discovery or replication analysis and at least nominally significant in the other analysis (p < 0.05), identifying plasma TG levels as a novel potential risk factor for 9 non-ASCVD diseases, including uterine leiomyoma (OR 1.19, 95% CI 1.10-1.29, p = 1.17 × 10-5).

    Conclusions: Taking a phenome-wide, two-sample MR approach, we identified causal associations between plasma TG levels and 19 disease traits across organ systems. Our findings suggest unrealized drug repurposing opportunities or adverse effects related to approved and emerging TG-lowering agents, as well as mechanistic insights for future studies.

    Funding: RD is supported by the National Institute of General Medical Sciences of the National Institutes of Health (NIH) (R35-GM124836) and the National Heart, Lung, and Blood Institute of the NIH (R01-HL139865 and R01-HL155915).